These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 11979307

  • 1. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S, Marasca R, Caracciolo F, Fazzi R, Papineschi F, Benedetti E, Guerrini F, Morabito F, Oliva E, Di Renzo N, Federico M, Petrini M, Torelli G, For GISL.
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 3. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P, Cornillet P, Deconinck E, Tourani JM, Gardembas M, Delain M, Abgrall JF, Kootz C, Milpied N.
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [Abstract] [Full Text] [Related]

  • 4. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
    Mahé B, Milpied N, Mellerin MP, Moreau P, Morineau N, Vigier M, Harousseau JL.
    Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
    [Abstract] [Full Text] [Related]

  • 5. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y.
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [Abstract] [Full Text] [Related]

  • 6. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [Abstract] [Full Text] [Related]

  • 7. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B, Li YX, Song YW, Jin J, Liu YP, Wang WH, Wang SL, Sun YT, Yu ZH, Liu XF.
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
    [Abstract] [Full Text] [Related]

  • 8. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A, Shi Y, Feng F, Lu S, He X, Han X.
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [Abstract] [Full Text] [Related]

  • 9. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K.
    Neoplasma; 2001 Sep; 48(6):501-5. PubMed ID: 11949845
    [Abstract] [Full Text] [Related]

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 11. Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system.
    Di Nicola M, Siena S, Corradini P, Bregni M, Milanesi M, Magni M, Ruffini PA, Ravagnani F, Tarella C, Gianni AM.
    Bone Marrow Transplant; 1996 Dec; 18(6):1117-21. PubMed ID: 8971381
    [Abstract] [Full Text] [Related]

  • 12. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D.
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [Abstract] [Full Text] [Related]

  • 13. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.
    Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G.
    J Clin Oncol; 2003 Nov 01; 21(21):3918-27. PubMed ID: 14517188
    [Abstract] [Full Text] [Related]

  • 14. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM.
    Bone Marrow Transplant; 2003 Dec 01; 32(12):1159-63. PubMed ID: 14647270
    [Abstract] [Full Text] [Related]

  • 15. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
    Berinstein NL, Buckstein R, Imrie K, Spaner D, Mangel J, Tompkins K, Pennell N, Reis M, Pavlin P, Lima A, Couvadia A, Robinson J, Richardson P.
    Bone Marrow Transplant; 2002 Feb 01; 29 Suppl 1():S14-7. PubMed ID: 11840156
    [Abstract] [Full Text] [Related]

  • 16. [Prognostic factors in low-grade lymphoma].
    Gandarillas MA, Conde E, Mazorra F, Cuadrado MA, Baro J, Garijo J, Recio M, Richard C, Iriondo A, Zubizarreta A.
    Sangre (Barc); 1998 Jun 01; 43(3):185-90. PubMed ID: 9741223
    [Abstract] [Full Text] [Related]

  • 17. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

  • 18. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
    Li QC, Yuan XL, Wang YF, Zou DH, Zhao YZ, Qiu LG.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 22; 88(4):254-7. PubMed ID: 18361837
    [Abstract] [Full Text] [Related]

  • 19. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY, Li YX, Zhao LJ, Gao YH, Liu XF, Gu DZ, Qian TN, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2004 Jul 22; 26(7):425-9. PubMed ID: 15355649
    [Abstract] [Full Text] [Related]

  • 20. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study.
    Ann Hematol; 2004 Jul 22; 83(7):414-9. PubMed ID: 15085385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.